What's going on with Race Oncology at the moment ?, page-34

Take all three pillars, add up the total potential MC of the treatments they could generate (purportedly ~$44bn p/a), multiply by 4 or 5. Let your jaw hang open at that figure, then work out the dollar value of the per-share price. It’s unlikely a biotech or pharma will spend $150bn+ on a buyout, so do some hefty discounting to bring the SP into a feasible buyout range and you get upwards of the price I floated.

I know a few people in here also agree as I pulled these figures from analyses that have been shared here before.

There’s an understandable hesitation in sharing these kinds of numbers because it’s frankly just so high. It seems pie in the sky. But that’s also why it is so hard to value Bisantrene accurately and a blue sky valuation is hard to measure right now.

I am approaching this whole buyout process as one of many very positive outcomes and I strongly believe that, if the three pillars are wholly successful, the true blue sky is much higher than many realise or will allow themselves to entertain!